Loading...
BDTX logo

Black Diamond Therapeutics, Inc.NasdaqGS:BDTX Stock Report

Market Cap US$128.9m
Share Price
US$2.22
US$9.86
77.5% undervalued intrinsic discount
1Y0.9%
7D-2.6%
1D
Portfolio Value
​
View

Black Diamond Therapeutics, Inc.

NasdaqGS:BDTX Stock Report

Market Cap: US$128.9m

Black Diamond Therapeutics (BDTX) Stock Overview

A clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. More details

BDTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Revenue is forecast to grow 70.67% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Earnings are forecast to decline by an average of 17.9% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months compared to the US market


BDTX Community Fair Values

Create Narrative

See what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Black Diamond Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Black Diamond Therapeutics
Historical stock prices
Current Share PriceUS$2.22
52 Week HighUS$4.94
52 Week LowUS$1.93
Beta3.34
1 Month Change-13.62%
3 Month Change-10.12%
1 Year Change0.91%
3 Year Change-5.13%
5 Year Change-82.53%
Change since IPO-94.38%

Recent News & Updates

Recent updates

Seeking Alpha • Mar 25

Black Diamond Therapeutics: Market Is Yawning About These Data, But I See Opportunity

Summary Black Diamond Therapeutics (BDTX) remains a 'Buy', as silevertinib shows promising efficacy in EGFR-mutant NSCLC with notable CNS activity. BDTX reported a 60% objective response rate and 86% CNS response rate in phase 2 silevertinib data, addressing key resistance mutations. Cash position supports operations into 2028, allowing BDTX to reach pivotal clinical catalysts before requiring additional funding. Risks include competitive combination regimens and the need for future data to confirm silevertinib’s clinical and regulatory viability. Read the full article on Seeking Alpha
Analysis Article • May 04

We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Mar 25

Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier

Summary Black Diamond Therapeutics' strategic deal with Servier makes BDTX undervalued, with a $70M upfront payment and potential $710M in milestone payments and royalties. BDTX is trading below its net cash of $2.30 per share, presenting a major buying opportunity despite past shareholder losses. Aggressive selling by Biotech Growth N.V. caused recent price volatility, but this creates a buying opportunity given BDTX's strong fundamentals. I expect BDTX to reach $3.00 per share soon as the market absorbs the seller's shares and recognizes the partnership's value. Read the full article on Seeking Alpha
Seeking Alpha • Mar 13

Black Diamond Therapeutics: In Decline, But Why?

Summary Black Diamond Therapeutics, Inc. shows promising developments in its pipeline updates, highlighting significant advancements in targeted cancer therapies. The financial overview reveals a stable cash position, supporting ongoing research and development efforts without immediate capital concerns. Strengths include a robust pipeline and innovative approach, while risks involve clinical trial uncertainties and market competition. Bottom-line summary: Black Diamond Therapeutics presents a compelling investment opportunity with strong potential, balanced by inherent biotech sector risks. Read the full article on Seeking Alpha
Seeking Alpha • Dec 30

Black Diamond Therapeutics: Speculative Buy With Precision Oncology Catalysts

Summary Black Diamond Therapeutics, Inc.'s BDTX-1535 showed a promising 42% ORR in Phase 2 trials for recurrent EGFR-mutant NSCLC, which addresses treatment-resistant mutations. The MasterKey platform enables targeting entire families of oncogenic mutations, offering potential solutions for underserved cancer populations like non-classical NSCLC and glioblastoma. BDTX’s $112.7 million cash reserves will support operations through Q2 2026. Restructuring efforts will prioritize high-value programs like BDTX-1535. Key milestones, including first-line NSCLC trial results and FDA feedback, are expected in Q1 2025, positioning BDTX-1535 for Phase 3 trials. At a P/B ratio of 1.3, BDTX trades at a discount compared to its sector, presenting a speculative “Buy” opportunity ahead of significant catalysts. Read the full article on Seeking Alpha
Analysis Article • Oct 30

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Oct 08

Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data

Summary Preliminary results from phase 2 study using BDTX-1535 for the treatment of 1st-line EGFRm NSCLC patients, expected in Q1 of 2025. Updated cohort results from the phase 2 study using BDTX-1535 for the treatment of 2nd-line/3rd-line EGFRm NSCLC patients, expected in Q1 of 2025. Company to meet with the FDA in Q1 of 2025 and provide update on possible registration study to move BDTX-1535 program forward in the clinic. The global non-small cell lung cancer market is projected to reach $36.9 million by 2031. Read the full article on Seeking Alpha
Seeking Alpha • Jun 27

Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive

Summary Black Diamond Therapeutics, Inc. is developing a next-generation EGFR inhibitor with promising early data in lung cancer. BDTX-1535 targets EGFR mutations, especially resistance drivers, with key data readouts expected in 2024 and early 2025. Black Diamond Therapeutics has a strong-enough cash position for now, but the success of their pipeline candidates will be crucial for long-term sustainability. Read the full article on Seeking Alpha
Analysis Article • May 21

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, Black Diamond...
Analysis Article • Jan 31

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jan 12

Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM

Summary Black Diamond Therapeutics is a precision oncology company targeting genetically defined cancers with its Masterkey approach. Besides NSCLC, BDTX also produced positive early data in recurrent GBM, a notoriously hard-to-treat disease. The company plans to initiate enrollments for expansion cohorts and seek FDA feedback for additional studies on various doses of BDTX-1535. Read the full article on Seeking Alpha
Analysis Article • Oct 26

Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • May 05

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Jan 16

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Oct 02

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Jul 02

Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

BDTXUS BiotechsUS Market
7D-2.6%1.1%1.5%
1Y0.9%35.8%28.6%

Return vs Industry: BDTX underperformed the US Biotechs industry which returned 33% over the past year.

Return vs Market: BDTX underperformed the US Market which returned 28.4% over the past year.

Price Volatility

Is BDTX's price volatile compared to industry and market?
BDTX volatility
BDTX Average Weekly Movement16.1%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: BDTX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: BDTX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201421Mark Vellecawww.blackdiamondtherapeutics.com

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company’s lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial.

Black Diamond Therapeutics, Inc. Fundamentals Summary

How do Black Diamond Therapeutics's earnings and revenue compare to its market cap?
BDTX fundamental statistics
Market capUS$128.93m
Earnings (TTM)-US$43.21m
Revenue (TTM)n/a
0.0x
P/S Ratio
-2.9x
P/E Ratio

Is BDTX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BDTX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$43.21m
Earnings-US$43.21m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.75
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did BDTX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/29 13:34
End of Day Share Price 2026/05/29 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Black Diamond Therapeutics, Inc. is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhiqiang ShuBerenberg
Arlinda LeeCanaccord Genuity
Ilya ZubkovFreedom Broker